Cargando…
Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen sp...
Autores principales: | Xu, Lianrong, Zhao, Yan, Pan, Fei, Zhu, Mengxia, Yao, Liqin, Liu, Yan, Feng, Jiangfang, Xiong, Jie, Chen, Xiuhua, Ren, Fanggang, Tan, Yanhong, Wang, Hongwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885806/ https://www.ncbi.nlm.nih.gov/pubmed/31828114 http://dx.doi.org/10.1155/2019/6502793 |
Ejemplares similares
-
To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors
por: Busker, Sander, et al.
Publicado: (2020) -
MiR-23-TrxR1 as a novel molecular axis in skeletal muscle differentiation
por: Mercatelli, Neri, et al.
Publicado: (2017) -
Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
por: Wang, Sicong, et al.
Publicado: (2023) -
TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport
por: Zhang, Yushuo, et al.
Publicado: (2017) -
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)